10x Genomics Corp (TXG): Company Projected Revenue

TXG (10x) - company brandmark

Compliance with Western export restrictions in China is hindering the expansion of 10x Genomics, Inc. (TXG) due to the sensitivity of biodata. Revenues are based on the sale of high-cost instruments and the regular sale of proprietary consumables. An innovative staff of geneticists is retained through generous RSUs. The trend in the company's sales performance helps assess commercial prospects, and 0.62 captures the current value of the indicator for future sales volume.

10x - TXG Company Future Revenue (period 07/04/2022 - 11/16/2026)

10x Genomics Corp (TXG) - metric breakdowns and financial figures

- stock quotes and analyst forecast:
- stock exchange capitalization data:
Fundamental company analysis:10x Genomics Inc TXG
Signature product of 10x Genomics Inc

The monopoly position of 10x Genomics, Inc. (TXG) in the field of spatial genome analysis and the expansion of Chromium systems create a steady revenue stream from the sale of high-margin reagents. The company's predictive sales model reflects the market discounting of these prospects, allowing investors to use revenue dynamics to promptly diagnose business model attrition or confirm the asset's growth potential prior to the publication of official financial reports.

Main competitors

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Revenue CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Company Projected Revenue|Company Expected Revenue RARE (Ultragenyx)|Company Future Sales Volume BEAM|Projected Sales Volume Sarepta Corp|Company Projected Revenue Twist Bioscience, Inc. (TWST)|Projected Sales Volume intelliatx.com (NTLA)|Stoke Therapeutics - Company Future Sales Volume|BioLife Solutions Inc (BLFS) - Company Expected Sales Volume|wavelifesciences.com - Projected Sales Volume|Maze Therapeutics Corp (MAZE) - Company Future Sales Volume|SION: Projected Sales Volume|Company Revenue Forecast PRME|Company Projected Revenue Taysha Gene Therapies|Company Revenue Forecast QURE (uniQure)|Company Projected Revenue MeiraGTx (MGTX)|REGENXBIO Corp - Company Revenue Forecast|Company Projected Revenue Solid Biosciences SLDB|OCGN - Company Future Sales Volume|pacb.com - Projected Sales Volume|Benitec (BNTC) - Company Future Sales Volume|DSGN: Projected Sales Volume|RCKT - Company Future Sales|FDMT: Company Future Sales|Company Revenue Forecast LXEO (lexeotx.com)|Company Projected Revenue Korro Bio Inc. (KRRO)|Company Projected Revenue Volume EDIT|Projected Sales Volume SLN (Silence Therapeutics PLC)|Company Future Revenue PRQR|CDXS - Company Projected Revenue|SGMO (Sangamo Therapeutics) - Company Revenue Forecast|NAUT: Projected Sales Volume|Company Revenue Forecast MGX|DTIL (precisionbiosciences.com) - Projected Sales Volume|Company Revenue Forecast GBIO (Generation Bio Co.)|Company Projected Revenue Boundless Bio (BOLD)|Exicure - Company Revenue Forecast|Projected Sales Volume IMNN (imunon.com)|Company Future Sales Phio Pharmaceuticals (PHIO)|MBIO: Company Future Sales Volume|Company Future Revenue RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Company Projected Revenue|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume